Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
No Thumbnail Available
Identifiers
Date
2021-10-05
Authors
Santoro, Francesco
Nunez-Gil, Ivan Javier
Vitale, Enrica
Viana-Llamas, Maria C.
Reche-Martinez, Begona
Romero-Pareja, Rodolfo
Feltez Guzman, Gisela
Fernandez Rozas, Inmaculada
Uribarri, Aitor
Becerra-Munoz, Victor Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bmj publishing group
Metrics
Export
Abstract
Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient.Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74 +/- 12 years vs 63 +/- 17 years, p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
COVID-19, pharmacology, clinical, Coronavirus disease 2019